Simponi approved for non-radiographic axial spondyloarthritis

Simponi (golimumab) is a monoclonal antibody against tumour necrosis factor (TNF).
Simponi (golimumab) is a monoclonal antibody against tumour necrosis factor (TNF).

Further information
View Simponi drug record
Summary of Product Characteristics
Manufacturer: MSD

The licensed indications for Simponi (golimumab) have been extended to include the treatment of severe active non-radiographic axial spondyloarthritis with objective signs of inflammation in patients who are intolerant of, or unresponsive to, treatment with NSAIDs.

The recommended dose for the new indication is 50mg by sc inj monthly on the same date each month.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases